ArticleGastroenterology & hepatology2008
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?
Article in Gastroenterology & hepatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Biliary sphincterotomy resets pancreaticobiliary pain refractory to intrasphincteric Botox injections in functional biliary pain.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Current treatment of biliary Sphincter of Oddi Dysfunction.Frontiers in medicine · 2024Review
- Botulinum Toxin A Use in the Gastrointestinal Tract: A Reappraisal After Three Decades.Gastroenterology & hepatology · 2023Article
- EndoFLIP assessment of pyloric sphincter in children: a single-center experience.Translational gastroenterology and hepatology · 2023Article
- Intra-sphincteric botulinum toxin in the management of functional biliary pain.Endoscopy international open · 2022Article
- The Multispecialty Toxin: A Literature Review of Botulinum Toxin.Plastic and reconstructive surgery. Global open · 2022Article
- Factors resulting in postoperative dysphagia following esophagectomy: a narrative review.Journal of thoracic disease · 2021Review
- Tailoring Therapy for Achalasia.Gastroenterology & hepatology · 2020Article
- Antidepressant-Like Action of Single Facial Injection of Botulinum Neurotoxin A is Associated with Augmented 5-HT Levels and BDNF/ERK/CREB Pathways in Mouse Brain.Neuroscience bulletin · 2019Article
- Pyloric Therapies for Gastroparesis.Current treatment options in gastroenterology · 2017Review
- A Case of Sub-Diaphragmatic Abscess after Injection of Botulinum Toxin to Treat Achalasia.ACG case reports journal · 2017Article
- Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Endoscopic treatment of gastroparesis.World journal of gastroenterology · 2015Review
- An update on the use of botulinum toxin therapy in Parkinson's disease.Current neurology and neuroscience reports · 2015Review
- Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A.Patient preference and adherence · 2015Review
- Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.Toxins · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The history of botulinum toxin is fascinating. First recognized as the cause of botulism nearly 200 years ago, it was originally feared as a deadly poison. Over the last 30 years, however, botulinum toxin has been transformed into a readily available medication used to treat a variety of medical disorders. Interest in the use of botulinum toxin has been particularly strong for patients with spastic smooth muscle disorders of the gastrointestinal tract. Patients with achalasia, diffuse esophageal spasm, gastroparesis, sphincter of Oddi dysfunction, and anal fissures have all been treated with botulinum toxin injections, often with impressive results. However, not all patients respond to botulinum toxin therapy, and large randomized controlled trials are lacking for many conditions commonly treated with botulinum toxin. This paper reviews the history, microbiology, and pharmacology of botulinum toxin, discusses its mechanism of action, and then presents recent evidence from the literature regarding the use of botulinum toxin for the treatment of a variety of gastrointestinal tract disorders.
Indexed as
Identifiers
21960915PMC3093735W1541025865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.